document incorporate reference incorporate scheringplough corporation part annual report shareholdersscheringplough corporation proxy iii statement annual meeting shareholder april item business term scheringplough company refer scheringplough corporation subsidiary indicate context scheringplough corporation hold company incorporate trademark indicate capital letter property license promote distribute scheringplough corporation subsidiary relate company subsidiary scheringplough engage discovery development manufacturing marketing pharmaceutical product worldwide discovery development effort target field human health occasionally application field animal health result effort company view animal health application mean maximize return investment discovery development company operate primarily prescription pharmaceutical marketplace appropriate company seek future seek regulatory approval switch prescription product overthecounter otc status mean extend product life cycle way otc marketplace mean maximize return investment discovery development prescription product sale include allergy product claritin loratadine claritin claritin syrup claritin prescription sale united states formulation account percent company consolidated worldwide sale percent large percentage company consolidated earning march company announce food drug administration fda accept company application switch indication claritin otc product november company announce fda approve formulation claritin original prescription strength otc medicine treatment allergy company begin ship otc claritin december united states company continue market clarinex desloratadine tablets treatment allergic rhinitis combine indication seasonal allergic rhinitis indication perennial allergic rhinitis treatment chronic idiopathic urticaria hive unknown cause ability company capture maintain market share clarinex otc claritin market depend number factor include additional entrant market allergy treatment clinical differentiation clarinex allergy treatment perception extent differentiation marketplace pricing differential otc claritin clarinex allergy treatment generic otc loratadine erosion rate otc claritin clarinex sale entry additional generic otc loratadine product brand secondgeneration antihistamine switch prescription otc status switch claritin otc status result rapid sharp material decline claritin sales united state sale claritin prescription product billion billion respectively percent percent respectively company consolidated worldwide sale year worldwide sale clarinex launch united states january million sale clarinex united states abroad materially adversely affect presence generic otc loratadine otc claritin market give anticipate contraction prescription antihistamine market light factor describe management believe company december introduction otc claritin introduction compete otc loratadine product december additional entrant generic otc loratadine product market likely rapid sharp material adverse effect company result operation indeterminate period time company merck inc merck enter agreement jointly develop market united states new prescription medicine cholesterolmanagement respiratory therapeutic area agreement cover development marketing coadministration zetia ezetimibe company novel cholesterol absorption inhibitor statins zetia oncedaily monotherapy ezetimibe oncedaily fixedcombination tablet simvastatin zocor merck cholesterolmodifye medicine oncedaily fixedcombination tablet contain claritin singulair treatment allergic rhinitis asthma singulair merck oncedaily leukotriene receptor antagonist treatment asthmain december cholesterolmanagement agreement expand include country world japan january scheringploughmerck pharmaceutical report result phase iii clinical trial fixedcombination tablet contain claritin singulair demonstrate sufficient add benefit treatment seasonal allergic rhinitis october ezetimibe approve sale germany market ezetrol october fda approve zetia use statin patient high cholesterol reduce ldlc bad cholesterol total cholesterol agreement company generally provide equal sharing development cost copromotion approve product company united states country world japan japan agreement exist general copromotion provide company provide equal physician detail effort bear cost sale force marketing product company share certain cost portion cost manufacturing promotion administration etc share profit agreement provide jointly own facility product result collaboration manufacture facility own merck company additional prescription product sell company include celestamine nasonex polaramine proventil allergyrespiratory caelyx cedax eulexin garamycin intron pegintron rebetol ribavirin remicade temodar antiinfective anticancer diprolene diprosone elocon lotrisone quadriderm valisone dermatological integrilin kdur nitrodur cardiovascular celestone diprospan subutex pharmaceuticals pegintron rebetol combination therapy hepatitis contribute substantially sale fourth quarter compete pegylate interferonbased combination product include brand ribavirin receive regulatory approval major market include united states management believe ability pegintron rebetol combination therapy maintain market share adversely affect introduction compete product animal health product include cepravin nuflor antimicrobials banamine nonsteroidal antiinflammatory ralgro growth promotant implant otomax otic product broad range vaccine specie parasiticide suture bandage nutritional product foot care otc sun care product include clear away wart remover scholl foot care product lotrimin tinactin antifungal ointment afrin nasal decongestant chlortrimeton antihistamine claritin allergy coricidin drixoral cold decongestant product correctol laxative bain soleil coppertone solarcaine sun care product net sale major product therapeutic category dollar million year end december percent change allergy respiratory clarinex claritin nasonex proventil allergy respiratory antiinfective anticancer intron franchise remicade temodar antiinfective anticancer cardiovascular integrilin kdur nitrodur cardiovascular dermatological pharmaceutical worldwide pharmaceutical animal health foot care otc otc claritin otc sun care consolidate net sale certain sale amount reclassify sell general administrative expense net sale comply eitf issue vendor income statement characterization consideration pay resell vendor product meaningful sale clarinex launch international market include claritin sale intron franchise consist intron pegintron rebetol segment information set forth page note consolidated financial statement company annual report shareholder incorporate reference prescription drug introduce known physician pharmacist hospitals manage care organization buy group train professional sale representative sell hospital certain manage care organization wholesale distributor retail pharmacist prescription product introduce known journal advertise direct mail advertising distribute sample physicians television radio internet print advertising medium animal health product promote veterinarian distributor animal producer foot care otc sun care product sell wholesale retail drug food chain mass merchandiser outlet promote directly consumer television radio internet print advertising media pharmaceutical industry highly competitive include large company substantial resource research product development advertising promotion field sell support numerous domestic international competitor industry principal competitive technique company product include research development new improved product high product quality varied dosage form strength switch prescription product nonprescription status united states company product subject increasingly competitive pricing manage care group institution federal state government entity agency buy group seek price discount rebate governmental pressure dispense generic product significantly reduce sale certain product long protect patent datum exclusivity arrangement fda company subsidiary license right number patent patent application united states abroad patent patent application relate company significant product include limitation clarinex claritin family product intron pegintron rebetol nasonex zetia materialimportance company compound patent loratadine expire june market exclusivity claritin expire december patent cover compound desloratadine formulation thereof method treatment desloratadine relate claritin set expire april month market exclusivity attach end desloratadine patent relate claritin expire october sixmonth period exclusivity grant company conduct pediatric clinical trial request fda patent subject litigation describe item legal proceeding worldwide company product sell trademark trademark consider aggregate material importance business protect registration common law united states market product sell raw material essential company available adequate quantity number potential supplier energy expect available company sufficient quantity meet operating requirement seasonal pattern pronounce effect consolidated operation company percent percent percent respectively consolidated net sale mckesson corporation major pharmaceutical health care product distributor percent percent percent respectively consolidated net sale amerisourcebergen corporation major pharmaceutical health care product distributor substantially sale united states foreign operation foreign activity carry primarily whollyowne subsidiary market potential adequate circumstance permit addition company represent market licensee distribution arrangement approximately employee outside united states foreign operation subject certain risk inherent conduct business overseas risk include possible nationalization expropriation importation limitation pricing restriction restrictive governmental action economic destabilization fluctuation foreign currency exchange rate impact company consolidated financial result additional information foreign operation management discussion analysis operation financial condition segment information begin page respectively company annual report shareholder incorporate reference research development company research activity primarily aim discover develop new enhance prescription product medical commercial significance company sponsor research development expenditure million million million respectively research expenditure represent approximately percent consolidated net sale approximately percent consolidated net sale approximately percent consolidated net sale company research activity concentrate therapeutic area allergic inflammatory disorder infectious disease oncology cardiovascular disease central nervous system disorder company substantial effort direct biotechnology gene therapy immunology research activity include expenditure internal research effort research collaboration partner pharmaceutical compound vary stage development predict compound available commercial sale government regulation pharmaceutical company subject extensive regulation number national state local agency particular importance fda jurisdiction company business administer requirement cover testing approval safety effectiveness manufacturing labeling marketing company product extent fda requirement andor review affect resource necessary develop new product bring market united states ongoing basis fda regulate facility procedure manufacture pharmaceutical product united states sale united states product facility manufacture accordance good manufacturing practice gmp establish fda fda periodically inspect company facility procedure evaluate compliance december company announce negotiation fda enter consent decree resolve issue involve company compliance current gmp certain manufacturing facility new jersey puerto rico company announce reach agreement fda consent decree resolve issue district court district new jersey approve consent decree term consent decree company pay total million government equal installment million installment pay second installment pay second quarter previously report company accrue million provision consent decree fourth quarter event certain action agree consent decree satisfactorily complete time fda assess payment deadline miss payment exceed million million year payment subject overall cap million company schedule complete revalidation plan december general addition payment describe product schedule revalidation certification consent decree certify month schedule date company cease production product certification obtain product schedule revalidation certification certify validate date validation schedule currently december finish drug september bulk active pharmaceutical ingredient fda assess payment percent net domestic sale uncertified product validation certify company expense payment incur connection agreement company decide discontinue manufacturing marketing certain old product consent decree include recall initiate early direct trade account lot theophylline usp tablet proventil albuterol sulfate usp repetabs proventil inhaler affect recall company discontinue market theophylline product june proventil repetabs available july total product represent annual sale approximately million company recall certain sterile human animal drug product manufacture manati puerto rico facility financial impact recall immaterial failure comply governmental regulation result delay release product delay approval new product seizure recall product suspension revocation authority necessary production sale product fine civil criminal sanction fda regulate conversion pharmaceutical prescription otc status company activity outside united states subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing company product regulatory requirement vary country country fda approval approval european medicine evaluation agency obtain product approval product comparable regulatory authority country outside united states european union case obtain prior marketing product country approval process rigorous country country time require approval long shorter require united states approval country assure product approve country international market company operate environment governmentmandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug enact acrosstheboard price cut method cost control recent year legislative proposal offer congress state legislature effect major change affect health care system change material company possible addition outpatient prescription drug benefit medicare states pass legislation federal state legislative administrative proposal possible include price patient reimbursement constraint medicine mandate discount supplemental rebate expansion exist governmental program new patient population restriction access certain product similar issue arise country outside united states possible predict outcome initiative effect operation cash flow reasonably estimate company subject jurisdiction federal state regulatory enforcement department agency federal trade commission ftc department justice department health human services united states company subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy environment date compliance federal state local environmental protection law materially adverse effect company company continue necessary expenditure environmental protection worldwide capital expenditure include approximately million environmental control purpose anticipate continued compliance environmental regulation significantly affect company financial statement competitive position additional information environmental matter legal environmental regulatory matter begin note consolidated financial statement company annual report shareholder incorporate reference employee approximately people employ company december available information company make annual report quarterly report form current report form amendment report file sec available free charge web site soon reasonably practicableafter material electronically file sec company address world wide web schering ploughcom company begin practice quarter report available company web site hour file cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalled forwardlooke statement subject risk uncertaintie identify forwardlooke statement use word expect plan estimate forecast project believe anticipate word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result regulatory issue status product approval development program litigation investigation carefully consider statement understand factor cause actual result differ company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement possible predict identify factor include follow significant portion net sale major pharmaceutical health care product distributor major retail chain united states consequently net sale quarterly growth comparison affect fluctuation buy pattern major distributor retail chain trade buyer fluctuation result seasonality pricing wholesaler buying decision factor competitive factor include technological advance attain competitor patent grant competitor new product competitor come market new indication competitive product generic prescription otc competition company product mature patent expire product increase pricing pressure united states abroad manage care organization institution government agency programs united states development consolidation customer increase pricing pressure result customer great influence prescription decision formulary decision policy government law regulation change law regulation affect domestic international operation enforcement thereof include law regulation result healthcare reform initiative united states state federal level country law regulation relate trade antitrust monetary fiscal policy taxis price control possible nationalization patent position highly uncertain patent dispute unusual adverse result patent dispute preclude commercialization product negatively impact sale exist product result injunctive relief payment financial remedy uncertaintie fda approval process regulatory approval process nonus country include limitation delay approval new product failure meet gmp establish fda governmental authority result delay release product seizure recall product suspension revocation authority necessary production sale product fine civil criminal sanction resolution manufacturing issue fda discuss report subject substantial risk uncertaintie risk uncertainty include time scope duration resolution manufacturing issue depend ability company assure fda quality reliability manufacturing system control extent remedial prospective obligation undertake company difficulty product development pharmaceutical product development highly uncertain product appear promise development fail reach market numerous reason found ineffective harmful effect clinical preclinical testing fail receive necessary regulatory approval turn economically feasible manufacturing cost factor precluded commercialization proprietary right efficacy safety concern respect market product scientifically justified leading recall withdrawal decline sale major product claritin clarinex intron pegintron rebetol capsules nasonex account material portion company revenue major product subject problem loss patent protection otc availability indicate claritin current potential otc competition previously unknown effect new effective treatment introduce product discontinue reason impact revenue significant legal factor include product liability claim litigation government investigation patent dispute withcompetitor environmental concern preclude commercialization product negatively affect profitability exist product economic factor company control include change inflation interest rate foreign currency exchange rate change tax law include change relate taxation foreign earning change accounting standard promulgate american institute certify public accountant financial accounting standard board securities exchange commission adverse company item property company corporate headquarters locate kenilworth new jersey principal manufacturing facility locate kenilworth new jersey miami florida omaha nebraska cleveland tennessee puerto rico argentina belgium canada france germany ireland italy japan mexico singapore spain company principal research facility locate kenilworth union new jersey palo alto san diego california elkhorn nebraska company announce reach agreement fda enter consent decree resolve issue involve company compliance current gmp certain manufacturing facility new jersey puerto rico refer government regulation section item additional information consent decree major portion property own company property generally maintain adequately insure generally good operating condition company manufacture facility capacity consider appropriate meet company need item legal proceeding background company responsibilitie environmental cleanup state local federal law include comprehensive environmental response compensation liability act commonly know superfund superfund site equivalent site state law company allege potentially responsible party prp company estimate obligation cleanup cost superfund site base information obtain federal environmental protection agency equivalent state agency andor study prepare independent engineer probable cost pay prps company record liability environmental assessment andor cleanup probable loss incur reasonably estimate company involve claim legal proceeding nature consider normal business include product liability case company adjust accrue liability reflect current good estimate probable loss exposure good estimate determinable company accrue minimum probable range liability record liability matter december relate expense incur year end december material expect insurance recovery consider determine cost environmentalrelate liability management believe matter discuss remainder section remote material liability excess amount accrue incur respect matter discuss remainder section note practicable estimate range reasonably possible loss reserve include financial statement resolution matter discuss remainder section individually aggregate material adverse effect company result operation financial condition management review status matter ongoing basis time time settle resolve term condition management believe good interest company company aware settlement matter type set forth remainder section particular investigation frequently involve fine andor penalty material financial condition result operation entity enter settlement assurance company prevail matter settlement reach acceptable term amount exceed amount reserve outcome predict environmental resident vicinity publicly own wastewater treatment plant barceloneta puerto rico file lawsuit plant owner operator numerous company discharge plant include subsidiary company damage injunctive relief relate odor allegedly come plant connect sewer lawsuit class action claim damage million discovery ongoing lawsuit patent mattersin february geneva pharmaceuticals inc geneva submit abbreviate new drug application anda fda seek market generic claritin tablet expiration company desloratadine compound patent company believe protect claritin geneva allege desloratadine compound patent invalid patent material company business march company file suit federal court seek rule geneva anda submission constitute infringement company desloratadine compound patent challenge patent merit addition geneva follow company similar anda submission generic claritin tablet zenith goldline pharmaceutical mylan pharmaceuticals inc teva pharmaceuticals usa inc teva ranbaxy pharmaceuticals inc genpharm incorporate perrigo company perrigo follow company similar anda submission generic claritin syrup teva copley pharmaceuticals inc novex pharma alpharma uspd inc taro pharmaceuticals usa inc morton grove pharmaceuticals inc perrigo andrx pharmaceuticals llc andrx impax laboratories inc impax similar anda submission generic claritind hour claritind hour formulation esi lederle inc lederle subsidiary wyeth similar anda submission generic claritin reditab formulation follow company submit paper new drug application paper nda section federal food drug cosmetic act seek market generic otc form claritin prior expiration company desloratadine compound patent whitehallrobin healthcare division wyeth otc reditab formulation mcneil consumer healthcare mcneil otc tablet perrigo otc tablet case company file suit federal court seek rule applicable anda paper nda submission propose marketing generic prescription otc product constitute infringement company desloratadine compound patent challenge patent merit august federal district court new jersey rule motion summary judgment find certain claim desloratadine compound patent anticipate prior patent valid september district court deny request reconsideration company appeal ruling appeal schedule argue april company anticipate appeal decide second half early ruling action defendant infringement desloratadine compound patent proceed company appeal successful company assert impax andrx andas generic claritind hour formulation infringe company patent cover claritind hour formulation issue resolve district court august geneva pharmaceuticals technology corp geneva pharmaceuticals river pharmaceutical llc river january teva submit separate anda fda seek market generic form rebetol ribavirin capsules united states expiration company patent cover ribavirin formulation geneva pharmaceutical river teva assert infringe company rebetol patent andor patent invalid rebetol patent material company business september october march company file suit federal court seek ruling anda submission geneva pharmaceutical river teva respectively constitute infringement company patent challenge company patent merit february company enter licensing agreement river settle patent litigation company river term agreement company grant river nonexclusive nonsublicensable license company ribavirin patent river pay company royalty ribavirin sale agreement affect river report patent litigation ribapharm inc agreement subject dismissal relevant lawsuit court patent litigation geneva teva temporarily stay party seek reach settlement january jury find company prime pac prrs porcine respiratory reproductive syndrome vaccine infringe patent own boehringer ingelheim vetmedica inc injunction issue august bar sale company vaccine company posttrial motion reversal jury verdict new trial deny september company appeal verdict affirm appellate court february discovery damage phase case ongoing investigation october company receive subpoena attorney office eastern district pennsylvania pursuant health insurance portability accountability act concern company contract pharmacy benefit manager pbms manage care organization provide disease management service connection marketing pharmaceutical product appear subpoena number address industry participant inquiry thing pharmaceutical marketing practice government inquiry focus thing company disease management marketing program arrangement comply federal health care law value disease management program marketing program arrangement include calculation rebate government company cooperate investigation march attorney office begin issue grand jury subpoena grand jury investigation appear focus transaction manage care organization government believe company offer provide deeply discount pharmaceutical product know nominally price product generally exclude medicaid rebate calculations free discount disease management service marketing program arrangement deliver value order place retain company major pharmaceutical product manage care organization formulary grand jury appear investigate thing transaction describe conduct relate thereto violate federal antikickback statute value item service describe include company calculation medicaid rebate outcome investigation include commencement civil andor criminal proceeding involve substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program company predict investigation affect marketing practice sale february company increase litigation reserve relate investigation investigation describe theus attorney office district massachusetts million increase litigation reserve reflect adjustment company estimate minimum liability relate investigation compliance generally accept accounting principle gaap gaap company require estimate recognize minimum liability loss probable well estimate loss gaap company require recognize liability company note total reserve reflect estimate final settlement adjudication matter possibly materially exceed aggregate liability accrue company materially adverse effect operation financial condition company adjustment consistent company policy review regularly status pende action investigation make adjustment appropriate company respond investigation department health human services department justice certain state certain industry company practice average wholesale price awp investigation include department justice review merit federal action file private entity behalf united states district court southern district florida investigation attorney office district massachusett inter alia awp set pharmaceutical company certain drug improperly exceed average price pay dispenser consequence result unlawful inflation certain government drug reimbursement base awp march company receive subpoena massachusetts attorney general office seek document concern use awp pricing andor marketing practice company cooperate investigation outcome investigation include imposition substantial fine penalty injunctive administrative remedy attorney office district massachusetts investigate company sale product repackage sale manage care organization include company medicaid good price calculation early november company serve additional grand jury subpoena attorney district massachusetts information subpoena seek broad range information concern company sale marketing clinical trial practice program respect intron rebetron temodar company sale marketing contact manage care organization doctor company offering provision grant honorarium item service value manage care organization physician group doctor educational institution company understand investigation focus certain sale marketing clinical trial practice conduct relate thereto certain instance relate use mention product indication fda approval obtain socalle offlabel use violation federal law regulation respect offlabel promotional activity investigation appear focus drug sample clinical trial grant item service value give provider incentivize prescribe abovementione product include offlabel use violation federal health care anti kickback law company implement certain change sale marketing clinical trial practice continue review practice ensure compliance relevant law regulation company cooperate investigation future sale intron rebetron temodar adversely affect company time predict ultimate impact sale outcome investigation include commencement civil andor criminal proceeding involve imposition substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program february company increase litigation reserve relate investigation attorney office district massachusetts describe paragraph paragraph immediately precede investigation describe attorney office eastern district pennsylvania million increase litigation reserve reflect adjustment company estimate minimum liability relate investigation compliance gaap gaap company require estimate recognize minimum liability loss probable well estimate loss gaap company require recognize liability company note total reserve reflect estimate final settlement adjudication matter possibly materially exceed aggregate liability accrue company materially adverse effect operation financial condition company adjustment consistent company policy review regularly status pende action investigation make adjustment appropriate attorney office new jersey fda office criminal investigation conduct investigation focus company product include ribavirin manufacture puerto rico company cooperate government investigation department justice antitrust division investigate company consumer product division enter agreement company low commission rate consumer product broker february antitrust division serve grand jury subpoena company seek document time company cooperate investigation security class action litigation february company state press release fda conducting inspection company manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current good manufacturing practice primarily relate production process control procedure day february lawsuit file district court district new jersey company certain name officer allege violation section securities exchange act rule bpromulgate thereunder additional lawsuit tenor follow plaintiff suit purport represent class shareholder purchase share company stock date early march february date press release april lawsuit file district court district new jersey company certain name officer allege substantially violation security exchange act allege putative class action describe paragraph allege violation section security act failure disclose information subject matter federal trade commission ftc administrative proceeding describe purport represent class shareholder purchase share company stock july march business day company issue press release relate ftc administrative proceeding complaint previously file complaint consolidate action district court district new jersey lead plaintiff florida state board administration appoint court july october consolidated amend complaint file allege violation describe second sentence paragraph section claim purport represent class shareholder purchase share company stock february company motion dismiss consolidated amend complaint deny discovery ongoing addition lawsuit describe immediately precede paragraph lawsuit file district court district new jersey lawsuit file new jersey state court company nominal defendant certain officer director director seek damage behalf company include disgorgement trading profit defendant allegedly obtain basis material nonpublic information complaint lawsuit relate issue describe company february press release allege failure disclose material information breach fiduciary duty director federal court lawsuit include allegation relate investigation attorney office eastern district pennsylvania district massachusetts ftc administrative proceed company lawsuit state texas warrick pharmaceuticals warrick company generic subsidiary describe lawsuit shareholder derivative action purport assert claim behalf company demand board director decision company pursue claim august plaintiffs new jersey state court shareholder derivative action move dismiss voluntarily complaint action motion grant shareholder derivative action pende district court district new jersey consolidate action early stage consolidate action coordinate pretrial purpose consolidated action describe immediately precede paragraph january company receive demand letter date december law firm involve derivative action describe behalf shareholder involve derivative action demand board director bring claim behalf company base allegation substantially similar allege derivative action january board director adopt board resolution establish evaluation committee consist director investigate review analyze fact circumstance surround allegation demand letter consolidate amend derivative action complaint describe reserve board authority discretion exercise business judgment respect proper disposition demand committee engage independent outside counsel advise issue report finding investigation independent director board late october report determine shareholder demand refuse find liability officer director november board adopt recommendation evaluation committee august prescription access litigation pal project bostonbase group form litigate drug company issue press release state pal member file lawsuit new jersey state court company december company serve amend complaint case suit pal purport class action allege thing company directtoconsumer advertising falsely depict benefit claritin violation new jersey consumer fraud act february company file motion dismiss case court dismiss complaint entirety failure state claim plaintiff appeal december pal file class action suit federal court massachusetts company september consolidated complaint file court result coordination multidistrict litigation panel federal court awp case country consolidate complaint allege company warrick conspire provider defraud consumer report fraudulently high awps prescription medication reimburse medicare thirdparty payer complaint seek declaratory judgment unspecified damage include treble damage company defendant number purport nationwide state class action lawsuit plaintiff seek refund purchase price laxative phenylpropanolaminecontaine coughcold remedy purchase pharmaceutical manufacturer codefendant lawsuit general plaintiff claim purchase pay product know certain defect medical risk attendant use lawsuit early stage discovery plaintiff theory recovery legally test court agree case forward class action number lawsuit involve product recall albuterolvancerilvancenase inhaler file company seek recovery personal injury death lawsuit punitive damage claim company settle california state court class action seek refund purchase price inhaler program issue million voucher free inhaler plus payment attorney fee court give final approval settlement october royaltiescontract matter company party arbitration proceeding biogen inc relate thing royalty payment thesearbitration settle october icn pharmaceuticals inc notify company intention begin alternative resolution dispute proceed company seek payment royalty rebetol provide company charge reduce charge indigent patient participate schering commitment care program antitrust ftc matter company defendant numerous antitrust action commence start state federal court independent retail pharmacy chain retail pharmacy consumer plaintiff allege price discrimination andor conspiracy company defendant restrain trade jointly refuse sell prescription drug discount price plaintiff company february agree settle federal class action behalf approximately twothird retail pharmacy united states total million pay district court illinois approve settlement federal class action seventh circuit court appeal dismiss appeal settlement subject review april certain plaintiff federal class action commence purport class action district court illinois company defendant settle previous federal class action complaint allege defendant conspire implement settlement commitment follow settlement discuss district court deny plaintiff motion preliminary injunction hear company settle dismiss motion state court retailer consumer action settlement amount material company federal court illinois remand conspiracy portion case retailer opt class action district court file federal court illinois jurisdiction robinsonpatman portion case plaintiff antitrust action generally seek treble damage unspecified injunction allegedly unlawful conduct april ftc start administrative proceeding company upshersmith inc upshersmith lederle complaint allege anticompetitive effect settlement patent lawsuit company lederle company upshersmith lawsuit settle related generic version kdur company longacte potassium chloride product subject andas file lederle upshersmith june administrative law judge oversee case issue decision patent litigation settlement comply law respect dismiss claim company appeal decision commission file ftc staff currently pende outcome proceeding result imposition injunctive administrative remedy follow commencement ftc administrative proceeding allege class action suit file behalf direct indirect purchaser kdur company upshersmith lederle federal state court suit allege essentially fact claim violation federal state antitrust law state statutory andor common law cause action pricing matter quarter warrick sue state texas june company subsidiary schering corporation add defendant lawsuit allege warrick supply state false report wholesale price cause state pay medicaid claim prescription warrick albuterol sulfate solution inhaler higherthanjustifie level state seek damage approximately million warrick include treble damage penalty outcome litigation result imposition fine penalty injunctive remedy company warrick defendant numerous lawsuit bring state federal court allege company warrick report inflated awps prescription pharmaceutical cause thirdparty payer excess reimbursement provider action allege company warrick fail report accurate price medicaid rebate program underpaid rebate state action begin october bring state attorney general private plaintiff nonprofit organization employee benefit fund allege violation federal state law include fraud antitrust racketeer influence corrupt organization act rico claim action seek unspecified damage include treble punitive damage sec inquiry relate litigation company provide information sec connection commission inquiry relate company meeting investor communication company believe comply applicable security law matter private plaintiff file federal putative litigations company kogan consolidated january allege violation section securities exchange act sec regulation fair disclosure relate alleged disclosure meeting investor refer precede paragraphtax matter october irs auditor assert report company liable additional tax tax year report allege interest rate swap company enter unrelated party recharacterize loan affiliate company result additional tax income tax seek irs auditor relate recharacterization approximately million plus interest company accrue million company tax adviser believe probable irs prevail matter item submission matter vote security holder applicable executive officer registrant follow information executive officer include accordance iii item officer elect serve year successor shall duly elect current position business experience age richard jay kogan present position chief executive officer chairman board chief executive officer president president chief executive officer reelect office president joseph connors present position executive vice president general counsel jack wyszomierski present position executive vice president chief financial officer cecil pickett phd present position vice president president schering plough executive vice president research institute discovery research schering plough research institute richard zahn present position vice president president schering laboratoriespresident schering laboratory geraldine foster present position senior vice president senior vice president investor investor relation relation corporate communication daniel nichols present position senior vice president tax kogan retire chief executive officer president later april current position business experience age john ryan present position senior vice president vice president human resource human resource scheringplough pharmaceuticals douglas gingerella present position vice president corporate staff vice president corporate audits audits thomas kelly present position vice president controller donald lemma phd present position vice president corporate vice president information information technology management bristolmyers squibb chief information officer vice president chief information officer etec system division apply materials inc director management information technology liposome company kevin moore present position vice president treasurer joseph larosa present position staff vice president staff vice president commercial law secretary associate senior legal director general counsel legal director item market registrant common equity relate stockholder matter common share dividend share price datum approximate number holder record set forth company annual report shareholder incorporate reference equity compensation plan information follow information relate plan equity security company issue employee director company plan equity security issue non employee stock incentive plan predecessor plan certain stock option transferable family member employeeoptionee relate trust plan category column column column number security weightedaverage number security remaining issue exercise exercise price available future issuance outstanding option outstanding option equity compensation warrant right warrant right plan exclude security reflect column equity compensation plan approve security holder stock incentive plan predecessor plan equity compensation plan approve security holder director defer compensation plan scheringplough ireland share purchase scheme total plan provide annual grant share common stock nonemployee director director defer award stock unit pay share common stock deferral period end plan permit employee reside ireland enjoy tax advantage christmas bonus pay pass trustee trustee purchase share common stock open market allocate share employee account irish pound employee defer year employee sell withdraw share allocate account year item select financial datum sixyear select financial statistical datum set forth company annual report shareholder incorporate reference item management discussion analysis financial condition result operation management discussion analysis operation financial condition set forth begin company annual report shareholder incorporate reference item quantitative qualitative disclosure market risk market risk disclosure set forth management discussion analysis operation financial condition begin company annual report shareholder incorporate reference item financial statement supplementary datum consolidate balance sheet december relate statement consolidated income consolidated shareholder equity consolidated cash flow year period end december note consolidated financial statement independent auditor report deloitte touche llp date february unaudite quarterly datum set forth begin company annual report shareholder incorporate reference item change disagreement accountant account financial disclosure applicable iii item director executive officer registrant information concern director nominee director set forth company proxy statement annualmeete shareholder april incorporate reference information require executive officer include file caption executive officer registrant item executive compensation executive compensation information set forth company proxy statement annual meeting shareholder april incorporate reference item security ownership certain beneficial owner management relate stockholder matter information concern security ownership certain beneficial owner management set forth company proxy statement annual meeting shareholder april incorporate reference item certain relationship relate transaction information concern certain relationship relate transaction set forth company proxy statement annual meeting shareholder april incorporate reference item control procedure management include chief executive officer chief financial officer evaluate company disclosure control procedure period day prior filing date conclude company disclosure control procedure effective ensure material information relate company consolidated subsidiary know conclude significant change internal control factor significantly affect internal control subsequent date recent evaluation include corrective action regard significant deficiency material weakness item exhibit financial statement schedule report form financial statement follow consolidated financial statement independent auditor report include company annual report shareholder page incorporate reference statement consolidated income year end december statement consolidated cash flow year end december consolidated balance sheet december statement consolidated shareholder equity year end december note consolidated financial statementsindependent auditor report financial statement schedule independent auditor report schedule valuation qualifying account schedule included omit applicable require require information set forth financial statement note thereto column omit schedule file omit information applicable financial statement percent own company account equity method omit consider individually aggregate constitute significant subsidiary exhibit exhibit number description complete copy certificate incorporation amend currently effect incorporate reference exhibit company quarterly report period end june form certificate amendment certificate incorporation incorporate reference exhibit company quarterly report period end june form certificate amendment certificate incorporation incorporate reference exhibit company quarterly report period end march form file complete copy bylaw amend currently effect incorporate reference exhibit company registration statement form file amendment bylaw effective september incorporate reference exhibit company quarterly report period end september form amendment bylaw effective april incorporate reference exhibit company quarterly report period end march form amendment bylaw effective december incorporate reference exhibit company annual report file right agreement company bank new york date june incorporate reference exhibit form file company june file form indenture company bank new york trustee file document bii form global note file document form participation right agreement company chase manhattan bank national association trustee incorporate reference exhibit company registration statement form amendment file exhibit description number company executive incentive plan amend trust relate thereto plan incorporate reference exhibit company quarterly report period end march form executive incentive plan amend restate october incorporate reference exhibit company annual report file trust agreement incorporate reference exhibit company annual report amendment trust agreement incorporate reference exhibit company quarterly report period end march form amend restate define contribution trust incorporate reference exhibit aii company annual report file company stock incentive plan amend incorporate reference exhibit company annual report file amendment december incorporate reference exhibit company annual report file amendment february file document company stock incentive plan amend incorporate reference exhibit company quarterly report period end september form amendment stock incentive plan incorporate reference exhibit company quarterly report period end march form file amendment february file document company stock incentive plan incorporate reference company proxy statement annual meeting shareholder april amendment february file document retirement agreement company richard jay kogan incorporate reference exhibit form file november file description exhibit number employment agreement company richard jay kogan amend incorporate reference exhibit eii company annual report amendment incorporate reference exhibit company quarterly report period end june form second amendment incorporate reference exhibit eii company annual report amendment incorporate reference exhibit company quarterly report period end september form fourth amendment incorporate reference exhibit company quarterly report period end march form fifth amendment incorporate reference exhibit eii company annual report sixth amendment incorporate reference exhibit company quarterly report period end june form file form employment agreement company executive officer effective change control incorporate reference exhibit eiv company annual report form amendment incorporate reference exhibit company quarterly report period end september form form amendment effective january incorporate reference exhibit company annual report form employment agreement company executive officer effective change control incorporate prior amendment january new agreement effective begin january incorporate reference exhibit eiic company annual report form file description exhibit number eiii supplement employment agreement effective change control describe exhibit eii document index company joseph connor incorporate reference exhibit evi company annual report form file eiv supplement employment agreement effective change control describe exhibit eii document index company jack wyszomierski incorporate reference exhibit evii company annual report form file supplement employment agreement effective change control describe exhibit eii document index company richard zahn incorporate reference exhibit eviii company annual report form file amend restate director defer compensation plan trust relate thereto incorporate reference exhibit company quarterly report period end september form trust agreement incorporate reference exhibit company annual report amendment trust agreement incorporate reference exhibit company quarterly report period end march form amend restate define contribution trust incorporate reference exhibit aii company annual report file description exhibit number supplemental executive retirement plan trust relate thereto incorporate reference exhibit company quarterly report period end march form amendment incorporate reference exhibit company quarterly report period end september form second amendment supplemental executive retirement plan effective october incorporate reference exhibit company annual report amend restate trust agreement incorporate reference exhibit company annual report file amend restate director stock award plan file document defer compensation plan incorporate reference exhibit company quarterly report period end september form deferred compensation plan amend restate october incorporate reference exhibit company annual report form file amend restate director defer stock equivalency program incorporate reference exhibit company quarterly report period end september form file company form split dollar agreement relate collateral assignment company executive officer incorporate reference exhibit company annual report amendment incorporate reference exhibit company quarterly report period end march form file exhibit description number company retirement benefit equalization plan second amendment effective october incorporate reference exhibit company annual report form incorporate reference exhibit company quarterly report period end march form amendment incorporate reference exhibit company quarterly report period end september form file cholesterol governance agreement date company merck inc party signatory thereto incorporate reference exhibit company current report form date october amendment cholesterol governance agreement date december company merck inc party signatory thereto incorporate reference exhibit company current report form date october master agreement date december company merck inc party signatory thereto incorporate reference exhibit company current report form date october consent decree permanent injunction date company party thereto incorporate reference exhibit company current report form date computation ratio earning fix charge file document financial section company annual report shareholder exception portion say annual report specifically incorporate reference form file document report shall deem file subsidiary registrant file document consent expert counsel file document power attorney file document compensatory plan contract arrangement note information omit exhibit pursuant request confidential treatment file separately security exchange commission pursuant rule securities exchange act amend exhibit applicable copy exhibit furnish request report form threemonth period end december company furnish current report form report file october item event regulation disclosure item financialstatement exhibit report file october item financial statement exhibit item regulation disclosure report file november item event regulation disclosure item financial statement exhibit signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize scheringplough corporation registrant date march thomas kelly thomas kelly vice president controller pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate richard jay kogan richard jay kogan carl mundy chief executive officer director president director jack wyszomierski jack wyszomierski richard osborne executive vice president chairman board director chief financial officer thomas kelly thomas kelly patricia russo vice president controller director principal accounting officer han becherer kathryn turner director director david komansky robert van oordt director director eugene mcgrath arthur weinbach director director donald miller director sthomas kelly date march thomas kelly attorneyinfact certification jack wyszomierski executive vice president chief financial officer certify review annual report scheringplough corporation registrant base knowledge annual report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover annual report base knowledge financial statement financial information include annual report fairly present material respect financial condition result operation cash flow registrant period present annual report registrant certify officer responsible establish maintain disclosure control procedure define exchange act rule registrant design disclosure control procedure ensure material information relate registrant include consolidated subsidiary known entity particularly period annualreport prepare evaluate effectiveness registrant disclosure control procedure date day prior filing date annual report evaluation date present annual report conclusion effectiveness disclosure control procedure base evaluation evaluation date registrant certify officer disclose base recent evaluation registrant auditor audit committee registrant board director person perform equivalent function significant deficiency design operation internal control adversely affect registrant ability record process summarize report financial datum identify registrant auditor material weakness internal control fraud material involve management employee significant role registrant internal control registrant certify officer indicate annual report significant change internal control factor significantly affect internal control subsequent date recent evaluation include corrective action regard significant deficiency material weaknesse date march jack wyszomierski jack wyszomierski executive vice president chief financial officer certification richard jay kogan chief executive officer president certify review annual report scheringplough corporation registrant base knowledge annual report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover annual report base knowledge financial statement financial information include annual report fairly present material respect financial condition result operation cash flow registrant period present annual report registrant certify officer responsible establish maintain disclosure control procedure define exchange act rule registrant design disclosure control procedure ensure material information relate registrant include consolidated subsidiary known entity particularly period annual report prepare evaluate effectiveness registrant disclosure control procedure date day prior filing date annual report evaluation date present annual report conclusion effectiveness disclosure control procedure base evaluation evaluation date registrant certify officer disclose base recent evaluation registrant auditor audit committee registrant board director person perform equivalent function significant deficiency design operation internal control adversely affect registrant ability record process summarize report financial datum identify registrant auditor material weakness internal control fraud material involve management employee significant role registrant internal control registrant certify officer indicate annual report significant change ininternal control factor significantly affect internal control subsequent date recent evaluation include corrective action regard significant deficiency material weakness date march richard jay kogan richard jay kogan chief executive officer president certification jack wyszomierski executive vice president chief financial officer scheringplough corporation certify pursuant section sarbanesoxley act annual report year end december annual report statement accompany fully complie requirement section securities exchange act usc information contain annual report fairly present material respect financial condition result operation scheringplough corporation certificate furnish solely purpose section file annual report date march jack wyszomierski jack wyszomierski executive vice president chief financial officer certification richard jay kogan chief executive officer president scheringplough corporation certify pursuant section sarbanesoxley act annual report year end december annual report statement accompany fully complie requirement section securities exchange act usc information contain annual report fairly present material respect financial condition result operation scheringplough corporation certificate furnish solely purpose section file annual report date march richard jay kogan richard jay kogan chief executive officer presidentindependent auditor report scheringplough corporation director shareholder audit consolidated financial statement scheringplough corporation subsidiary december year period end december issue report thereon date february financial statement report include annual report shareholder incorporate reference audits include financial statement schedule scheringplough corporation subsidiary list item financial statement schedule responsibility company management responsibility express opinion base audits opinion financial statement schedule consider relation basic consolidated financial statement take present fairly material respect information set forth sdeloitte touche llp parsippany new jersey february schedule scheringplough corporation subsidiary valuation qualifying account year end december dollar million valuation qualifying account deduct asset apply allowance account receivable reserve reserve reserve doubtful cash claim account discount total balance beginning year addition charge cost expense deduction reserve effect foreign exchange balance end year balance beginning year addition charge cost expense deduction reserve effect foreign exchange balance end year balance beginning year addition charge cost expense deduction reserve effect foreign exchange balance end year